Sickle Cell Disease Treatment Market to Reach $7.2 Billion by 2035

Sickle cell disease treatment market was valued at $2.5 billion in 2025 and is projected to reach $7.2 billion by 2035, growing at a CAGR of 11.3% during 2026–2035. The increasing global burden of genetic blood disorders, along with rising adoption of disease-modifying and advanced therapeutics, is significantly driving market expansion. Sickle cell disease (SCD) remains one of the most prevalent inherited blood disorders worldwide, requiring lifelong treatment and management, thereby ensuring consistent demand for pharmacological and supportive therapies.

Browse the full report description of “Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Therapy, Curative Therapy, Supportive Care), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Route of Administration (Oral, Injectable), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/sickle-cell-disease-treatment-market

According to the World Health Organization, more than 300,000 infants are born annually with sickle cell disease, with a large proportion occurring in Africa and South Asia. The organization further highlights that up to 90% of affected children in low-income regions die before the age of five due to lack of timely diagnosis and treatment access. This significant unmet medical need is driving governments and healthcare organizations to expand screening programs, improve treatment accessibility, and invest in disease management infrastructure. As a result, demand for established therapies such as hydroxyurea, iron chelation drugs, and newer biologics is increasing steadily across both developed and emerging markets. Pharmacological therapy remains the dominant and fastest-growing segment due to its widespread adoption, chronic usage patterns, and strong commercial availability. Drugs such as hemoglobin modulators, anti-adhesion biologics, and amino acid therapies are witnessing increased uptake as they directly reduce disease complications and improve patient outcomes. In addition, growing awareness initiatives and national screening programs are contributing to earlier diagnosis, thereby expanding the treated patient population.

Globally, regulatory agencies are increasingly prioritizing rare disease drug development, accelerating approvals and commercialization of innovative therapies. The U.S. Food and Drug Administration has expanded orphan drug designations and fast-track approvals, enabling quicker market entry for SCD treatments. This regulatory momentum is encouraging pharmaceutical companies to invest in targeted therapies and expand their rare disease portfolios, supporting sustained revenue growth within the market. Data from IQVIA indicates that global spending on specialty and rare disease medicines continues to grow annually, driven by high-cost biologics and innovative therapies. This trend supports premium pricing strategies and strengthens the commercial viability of SCD treatments. Increasing healthcare expenditure, particularly in emerging economies, is further improving access to essential medicines and boosting treatment adoption rates.

Innovation and Strategic Developments Shaping Market Growth

• In January 2026, Caring Cross and Boston Children's Hospital collaborated to expand global access to gene therapies for sickle cell disease by making them more affordable and scalable. The partnership involves licensing an innovative lentiviral-based BCL11A therapy that boosts fetal hemoglobin production, offering the potential for a long-term or lifelong treatment.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o By Treatment Type
  o By Distribution Channel
  o By Route of Administration

Competitive Landscape – Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Sickle Cell Disease Treatment Market Report Segment

By Treatment Type

• Pharmacological Therapy
• Curative Therapy
• Supportive Care

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Route of Administration

• Oral
• Injectable

Global Sickle Cell Disease Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/sickle-cell-disease-treatment-market